|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ:
Changing profiles of cancer burden worldwide and in China: A
secondary analysis of the global cancer statistics 2020. Chin Med J
(Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu X, Zhang Z, Li X, Lin Q, Chen G, Lu J,
Zeng Y, Hu D, Huang K, Lin Z and Yan J: Poorer prognosis of primary
signet-ring cell carcinoma of the breast compared with mucinous
carcinoma. PLoS One. 11:e01620882016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Frost AR, Terahata S, Yeh IT, Siegel RS,
Overmoyer B and Silverberg SG: The significance of signet ring
cells in infiltrating lobular carcinoma of the breast. Arch Pathol
Lab Med. 119:64–68. 1995.PubMed/NCBI
|
|
5
|
Mehdi M, Kong AL, Frebault J, Huang S,
Huang CC and Cortina CS: Prognostic outcomes of signet ring cell
carcinoma of the breast. J Surg Res. 264:138–148. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li X, Feng YF, Wei WD, Liu P, Xie ZM, Wang
J and Xie XM: Signet-ring cell carcinoma of the breast: A case
report. World J Surg Oncol. 11:1832013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuroda N, Fujishima N, Ohara M, Hirouchi
T, Mizuno K and Lee GH: Invasive ductal carcinoma of the breast
with signet-ring cell and mucinous carcinoma components: Diagnostic
utility of immunocytochemistry of signet-ring cells in aspiration
cytology materials. Diagn Cytopathol. 35:171–173. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chatterjee D, Bal A, Das A, Kohli PS,
Singh G and Mittal BR: Invasive duct carcinoma of the breast with
dominant signet-ring cell differentiation: A microsatellite stable
tumor with aggressive behavior. Appl Immunohistochem Mol Morphol.
25:720–724. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hull MT, Seo IS, Battersby JS and Csicsko
JF: Signet-ring cell carcinoma of the breast: A clinicopathologic
study of 24 cases. Am J Clin Pathol. 73:31–35. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Merino MJ and Livolsi VA: Signet ring
carcinoma of the female breast: A clinicopathologic analysis of 24
cases. Cancer. 48:1830–1837. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Giuliano AE, Connolly JL, Edge SB,
Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ and
Hortobagyi GN: Breast cancer-major changes in the American joint
committee on cancer eighth edition cancer staging manual. CA Cancer
J Clin. 67:290–303. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mor V, Laliberte L, Morris JN and Wiemann
M: The karnofsky performance status scale. An examination of its
reliability and validity in a research setting. Cancer.
53:2002–2007. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Karabagli P and Kilic H: Primary pure
signet cell carcinoma of the breast: A case report and review of
the literature. Breast Cancer. 20:363–366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sinn HP and Kreipe H: A brief overview of
the WHO classification of breast tumors, 4th edition, focusing on
issues and updates from the 3rd edition. Breast Care (Basel).
8:149–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tot T: The role of cytokeratins 20 and 7
and estrogen receptor analysis in separation of metastatic lobular
carcinoma of the breast and metastatic signet ring cell carcinoma
of the gastrointestinal tract. APMIS. 108:467–472. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Duan YS, Mao QX, Li LF, Sun YD, Wang L and
Cui SD: Intertumoral heterogeneity of molecular phenotype and
analysis of prognosis in multifocal and multicentric breast cancer.
Zhonghua Zhong Liu Za Zhi. 38:833–838. 2016.(In Chinese).
PubMed/NCBI
|
|
17
|
Nguyen D, Yu J, Reinhold WC and Yang SX:
Association of independent prognostic factors and treatment
modality with survival and recurrence outcomes in breast cancer.
JAMA Netw Open. 3:e2072132020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deniz M, DeGregorio A, DeGregorio N, Bekes
I, Widschwendter P, Schochter F, Ernst K, Scholz C, Bauer EC,
Aivazova-Fuchs V, et al: Differential prognostic relevance of
patho-anatomical factors among different tumor-biological subsets
of breast cancer: Results from the adjuvant SUCCESS A study.
Breast. 44:81–89. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Evcimik T, Degerli MS and Bilgic T: The
effect of prognostic factors on long-term protection in breast
cancer. Cureus. 12:e88782020.PubMed/NCBI
|
|
20
|
Mohar-Betancourt A, Alvarado-Miranda A,
Torres-Dominguez JA, Cabrera P, Lara-Medina F, Villarreal-Gómez YS
and Reynoso-Noverón N: Prognostic factors in patients with breast
cancer and brain metastasis as the first site of recurrence. Salud
Publica Mex. 60:141–150. 2018.(In Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kanyilmaz G, Yavuz BB, Aktan M, Karaağaç
M, Uyar M and Findik S: Prognostic importance of Ki-67 in breast
cancer and its relationship with other prognostic factors. Eur J
Breast Health. 15:256–261. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huszno J, Kolosza Z and Grzybowska E:
BRCA1 mutation in breast cancer patients: Analysis of prognostic
factors and survival. Oncol Lett. 17:1986–1995. 2019.PubMed/NCBI
|
